Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Down 60.0% in April

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 14,050 shares, a decrease of 60.0% from the April 15th total of 35,087 shares. Based on an average daily volume of 12,279 shares, the short-interest ratio is currently 1.1 days. Currently, 0.9% of the company’s shares are sold short.

Aethlon Medical Stock Performance

Shares of AEMD opened at $2.10 on Friday. The firm has a market cap of $3.29 million, a P/E ratio of -0.14 and a beta of 1.50. Aethlon Medical has a twelve month low of $1.36 and a twelve month high of $34.05. The firm’s 50 day moving average price is $2.15 and its two-hundred day moving average price is $2.81.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Thursday, February 12th. The medical equipment provider reported ($2.45) EPS for the quarter, missing analysts’ consensus estimates of ($2.01) by ($0.44). On average, sell-side analysts anticipate that Aethlon Medical will post -9.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. Institutional investors own 1.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aethlon Medical presently has an average rating of “Reduce”.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.